BioSpecifics Technologies (BSTC) is a commercial-stage biotech company engaged in the development and commercialization of injectable collagenase for a broad range of clinical indications. Currently injectable collagenase is marketed as Xiaflex for a condition known as Dupuytren's Contracture. BioSpecifics has tremendous opportunities in Xiaflex and the shares of the company have huge upside potential over the medium-term.
BioSpecifics is currently conducting Phase II clinical trials of Xiaflex for two indications, human lipoma and canine lipoma. BioSpecifics is not the only company developing Xiaflex. In fact, its strategic partner Auxilium (AUXL) has been marketing Xiaflex for Dupuytren's Contracture and conducting clinical trials of Xiaflex for Peyronie's Disease, Frozen Shoulder (Adhesive Capsulitis) and Cellulite (Edematous Fibrosclerotic...
Only subscribers can access this article, which is part of the PRO research library covering 3,591 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: